TCann interprets the regulatory framework to assist the medical community in accessing medicinal cannabis
THERAPEUTIC GOODS ADMINISTRATION
- Authorised Prescriber (AP) – authorisation of doctor for a group of patients
- Special Access Scheme (SAS) – authorisation for an individual patient
- Category A - Patients who are seriously ill with a condition from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of early treatment.
- Category B - Patients that do not fit the Category A. A doctor can choose to use Category B, even where the patient meets the Category A definition. This is the most applicable SAS category for medicinal cannabis.
MEDICINAL CANNABIS E-COURSES
TCann will provide Medicinal Cannabis E-Courses with the aim to ensure the Australian medical class a higher level of knowledge of the endocannabinoid system and cannabinoid therapies
- The Health Effects of Cannabis and Cannabinoids
- 27th Annual Symposium of the International Cannabinoid Research Society
- Cannabis: The Evidence for Medical Use
- The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain
- Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis
- Information for Health Care Professionals: Cannabis and the Cannabonoids (Health Canada, 2013)
- Access to Cannabis for Medicinal Purposes-Daily amount fact sheet (Dosage)
- Cannabidiol: a promising drug for neurodegenerative disorders?
- Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
- The endocannabinoid system and cancer: therapeutic implication
- Therapeutic Uses of Cannabis
- An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies
- Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society
- A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment